Armstrong Henry H Associates Inc. Has $60.78 Million Stock Position in Johnson & Johnson $JNJ

Armstrong Henry H Associates Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 0.8% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 327,811 shares of the company’s stock after selling 2,668 shares during the period. Johnson & Johnson comprises approximately 5.5% of Armstrong Henry H Associates Inc.’s holdings, making the stock its 4th largest holding. Armstrong Henry H Associates Inc.’s holdings in Johnson & Johnson were worth $60,783,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clark Asset Management LLC grew its stake in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the period. Treasurer of the State of North Carolina lifted its stake in Johnson & Johnson by 8.3% in the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after buying an additional 94,957 shares during the period. Apexium Financial LP boosted its holdings in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB grew its position in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after buying an additional 6,566 shares during the period. Finally, Winnow Wealth LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $295,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on JNJ. JPMorgan Chase & Co. lifted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 16th. Cowen reiterated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Daiwa America raised shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Bank of America upped their price objective on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research report on Monday. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $208.35.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $214.41 on Tuesday. The stock has a market capitalization of $516.58 billion, a price-to-earnings ratio of 20.70, a PEG ratio of 2.36 and a beta of 0.36. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.19. The firm has a fifty day simple moving average of $196.61 and a 200 day simple moving average of $177.85. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.